Efficacy and safety of adamgammadex for reversing rocuronium-induced deep neuromuscular block: a multicentre, randomised, double-blind, positive-controlled phase III trial
British Journal of Anaesthesia · 2025
DOI: 10.1016/j.bja.2025.04.031 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift British Journal of Anaesthesia, 2025. Verfasst von Yanhua Zhao und 27 weiteren Autor:innen. Beteiligte Einrichtung: Department of Anaesthesiology, Ren Ji Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China; Key Laboratory of Anaesthesiology …. Hauptthemen laut MEDLINE: Rocuronium, Neuromuscular Blockade, Neuromuscular Nondepolarizing Agents, gamma-Cyclodextrins. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 15 Literaturangaben.
Abstract (Originalsprache)
BACKGROUND: Adamgammadex, a newly developed modified γ-cyclodextrin derivative, has demonstrated efficacy in reversing deep rocuronium-induced neuromuscular block in early clinical trials. METHODS: This multicentre, randomised, double-blind, positive-controlled, noninferiority phase III clinical trial aimed to investigate the efficacy and safety of adamagammadex compared with sugammadex in reversing deep rocuronium-induced neuromuscular block. In total, 321 patients were randomly assigned to either the adamgammadex 8 mg kg-1 group or the sugammadex 4 mg kg-1 group. The primary outcome was the success rate of antagonism, defined as recovery of the train-of-four ratio (TOFR) to 0.9 within 10 min. Standard safety data were collected throughout the trial period. RESULTS: For the primary efficacy outcome, the success rate for recovery of TOFR to 0.9 was 98.7% in the adamgammadex group and 100% in the sugammadex group, with an observed difference of -1.3% (95% confidence interval [CI] -4.6%, 1.2%). The lower limit of -4.6% was higher than the noninferiority margin of -10%. For the key secondary efficacy outcomes, the median (interquartile range) time from administration of adamgammadex or sugammadex to recovery of TOFR to 0.9 was 2.5 (2.0, 3.2) min and 2.2 (1.7, 2.7) min, respectively. The difference was 0.5 min (95% CI 0.3, 0.7), and the upper limit of 0.7 min was lower than the noninferiority margin of 5 min. We observed no inferiority in secondary efficacy outcomes. There was no significant difference in the safety profile between adamgammadex and sugammadex. CONCLUSIONS: Adamgammadex was noninferior to sugammadex in reversing deep neuromuscular block from rocuronium. CLINICAL TRIAL REGISTRATION: Chinese Clinical Trial Registry (ChiCTR2200056471, registered February 6, 2022; https://www.chictr.org.cn/showproj.html?proj=141077).
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Anaesthesiology, Ren Ji Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China; Key Laboratory of Anaesthesiology (Shanghai Jiao Tong University), Ministry of Education, Shanghai, Chin…
- Department of Anaesthesiology, Quanzhou First Hospital Affiliated to Fujian Medical University, Quanzhou, China.
- Department of Anaesthesiology, The First Affiliated Hospital of Soochow University, Suzhou, China.
- Department of Anaesthesiology, Tongji Hospital of Tongji University, Shanghai, China.
- Department of Anaesthesiology, The 900 Hospital of the Chinese People's Liberation Army Joint Logistic Support Force, Fuzhou, China.
- Department of Anaesthesiology, West China Hospital, Sichuan University, Chengdu, China.
Zitieren
APA
Zhao, Y., Ren, Y., Xie, W., Wang, Y., Lei, Y., Zhu, Y., Zhang, X., Wu, X., Guo, X., Jiang, Y., Wang, S., Lei, Q., You, J., Yu, Y., Zhou, Y., Zhou, W., Xu, G., Li, C., Gu, Z., …, & Yu, W. (2025). Efficacy and safety of adamgammadex for reversing rocuronium-induced deep neuromuscular block: a multicentre, randomised, double-blind, positive-controlled phase III trial. British Journal of Anaesthesia. https://doi.org/10.1016/j.bja.2025.04.031
Vancouver
Zhao Y, Ren Y, Xie W, Wang Y, Lei Y, Zhu Y, et al. Efficacy and safety of adamgammadex for reversing rocuronium-induced deep neuromuscular block: a multicentre, randomised, double-blind, positive-controlled phase III trial. British Journal of Anaesthesia. 2025. doi:10.1016/j.bja.2025.04.031
BibTeX
@article{Zhao2025,
author = {Zhao, Yanhua and Ren, Yuqing and Xie, Wenqin and Wang, Yulan and Lei, Yishan and Zhu, Yingxia and Zhang, Xiaoqing and Wu, Xiaozhi and Guo, Xiaoming and Jiang, Yingying and Wang, Saiying and Lei, Qian and You, Jiyue and Yu, Yonghao and Zhou, Yinhui and Zhou, Wenjuan and Xu, Guohai and Li, Chang and Gu, Zhengfeng and Luo, Foquan and Wang, Hongfa and Chen, Junping and Wang, Ruichun and Qi, Youmao and Jie, Qing and Su, Diansan and Gu, Xiyao and Yu, Weifeng},
title = {Efficacy and safety of adamgammadex for reversing rocuronium-induced deep neuromuscular block: a multicentre, randomised, double-blind, positive-controlled phase III trial},
journal = {British Journal of Anaesthesia},
year = {2025},
doi = {10.1016/j.bja.2025.04.031}
}
EUVIMED